215 patents
Utility
Chemical Compounds
11 Jan 24
JEFFREY WALLACE JOHANNES, SUDHIR MAHADEO HANDE, AVIPSA GHOSH, XIAOLAN ZHENG, MARTIN PACKER, SEBASTIEN LOUIS DEGORCE
Filed: 14 Sep 23
Utility
Automated Assessment of Wound Tissue
4 Jan 24
A method of assessing a wound in a subject is provided.
Yinhai WANG, Adrian Mark FREEMAN
Filed: 11 Nov 21
Utility
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
21 Dec 23
Jonas BRÅNALT, Maria JOHANSSON, Anneli NORDQVIST, Gavin O'MAHONY, Marianne SWANSON
Filed: 20 Jun 23
Utility
Adjuvant Durvalumab in Combination with Chemotherapy for Treatment of Cancer
21 Dec 23
The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient's minimal residual status.
Phillip DENNIS, Lynne POOLE, Rena MAY
Filed: 11 Oct 21
Utility
PCSK9 Inhibitors and Methods of Use Thereof
21 Dec 23
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
Michael H. Serrano-Wu, Brian K. Hubbard, Virendar Kaushik, Doug Daniels
Filed: 25 Jan 23
Utility
Combination Therapy for Treating Cancer
23 Nov 23
The present disclosure relates, in general, to therapeutic combinations, and to corresponding methods of treatment, pharmaceutical compositions, and kits.
ELISABETTA LEO
Filed: 7 Oct 21
Utility
Amido Heteroaromatic Compounds
23 Nov 23
Daniel Tor PETTERSEN, Stéphanie Marcelle GUERET, Nidhal SELMI, Erik Lars MALMERBERG, Tord Bertil INGHARDT, Jan Åke LINDBERG, Jens Peter BRANDT, Jon Paul JANET, Björn Erik Anton HOLM
Filed: 18 May 23
Utility
Combination
23 Nov 23
The present invention features methods of treating cancer with an immunomodulatory agent, such as an anti-PD-L1 antibody or an antigen-binding fragment thereof, and an antisense compound targeted to STAT3 in a subject in need thereof.
Richard WOESSNER, Patricia Elizabeth MCCOON, Paul Dermot LYNE
Filed: 13 Oct 22
Utility
Compounds and Their Use In Treating Cancer
23 Nov 23
Iacovos Neal Michaelides, Ulf Börjesson, Thomas George Christopher Hayhow, Jason Grant Kettle, Gavin William Collie, Robert Ian Storer, Christoph Grebner, Matthew William Dampier Perry, Sharanjeet Kaur Bagal, Charlene Fallan
Filed: 29 Sep 21
Utility
Biomarkers for Predicting Overall Survival In Recorrent/metastatic Head and Neck Squamous Cell Carcinoma
23 Nov 23
The present disclosure generally relates to methods for treating head and neck squamous cell carcinoma patients based on use of blood-based tumor mutation burden, PD-L1 expression, expression levels of immunomodulators, pro-angiogenesis markers and pro-inflammatory markers and/or identification of mutations in circulating tumor DNA.
Weimin LI, Jiabu YE, Han SI, Nassim MORSLI, Qu ZHANG, Sophie WILDSMITH
Filed: 12 May 21
Utility
Arginase Inhibitors and Methods of Use Thereof
16 Nov 23
Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
Filed: 10 Jul 23
Utility
Combination of Zibotentan and Dapagliflozin for the Treatment of Endothelin Related Diseases
16 Nov 23
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES, Anne-Kristina MERCIER, Mikael SUNNÅKER
Filed: 23 Jun 23
Utility
ANTI-IFNAR1 Dosing Regime for Subcutaneous Injection
16 Nov 23
The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease.
Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Sr., Joachim ALMQUIST, Thomas ROUSE
Filed: 21 Apr 23
Utility
PCSK9 Inhibitors and Methods of Treatment Using Same
9 Nov 23
The present disclosure provides dosages and methods for treating a disease associated with proprotein convertase subtilisin/kexin type 9 (PCSK9).
Tina RYDÉN-BERGSTEN, Dinko REKIC, Catarina NILSSON, Jane KNÖCHEL
Filed: 16 Sep 21
Utility
Spirocyclic Compounds
9 Nov 23
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof.
JAMES MICHAEL SMITH, GRAEME RICHARD ROBB, PIOTR ANTONI RAUBO, BERNARD CHRISTOPHE BARLAAM, IAIN ALEXANDER CUMMING
Filed: 15 Jun 23
Utility
Pharmaceutical Compositions Comprising an Antisense Oligonucleotide for Oral Administration
9 Nov 23
A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating.
Anna TIVESTEN, Nigel DAVIES, Marie ELEBRING, Peter GENNEMARK, Mariagrazia MARUCCI, Niclas CLEMMENSEN, Hanna MATIC, Okky PUTRA, Pratik Pankaj UPADHYAY, Katrin WALTER, Lloyd TILLMAN, Luis DELLAMARY, Andreas RÅDEVIK
Filed: 16 Sep 21
Utility
Atr Inhibitors for the Treatment of Cancer
2 Nov 23
This specification discloses the use of an ATR inhibitor, preferably in combination with a taxane, for the treatment of cancer in a particular subset of patients who have previously received immunotherapy.
Simon Andrew SMITH, Emma Jane DEAN, Glen CLACK, Jeeyun LEE
Filed: 10 May 21
Utility
Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors
2 Nov 23
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
GORDON MOODY, MARIA LETIZIA GIARDINO TORCHIA, MICHAEL GLEN OVERSTREET, RYAN GILBRETH
Filed: 23 Apr 21
Utility
Compounds and Their Use
2 Nov 23
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein.
Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM, Giulia Bergonzini, Henrik Graden, Lars Johan Andreas Ulander
Filed: 22 Feb 23
Utility
Methods for Treating Severe Asthma In Patients with Nasal Polyposis
2 Nov 23
Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
MARIA ESTHER GARCIA GIL, JAMES ZANGRILLI, ANNE BURDEN, JAMES KREINDLER
Filed: 27 Mar 23